Zoetis Inc. ZTS
Set alert
79.72 USD +1.45 +1.85%
At close · Oct 30
79.29 -0.43 -0.54%
After hours · Oct 30, 7:57 PM ET
79.22 Day range 80.60
69.10 52-week range 144.35
- YTD
- -36.64%
- 1 year
- -44.68%
- Open
- 79.84
- Prev close
- 78.27
- Mkt cap
- 32.94B
- Vol
- 4.12M
- Avg vol
- 5.00M
- EPS
- 6.08
- P/E
- 13.11
- Div yield
- 2.69%
More statistics
- Low
- 79.22
- High
- 80.60
- Forward P/E
- 12.44
- Beta
- 0.74
- Short ratio
- 3.99
- Inst. own
- 100.27%
- Dividend
- 2.12
- Ex-div date
- Oct 29, 2026
- Earnings
- Nov 5, 2026
- 50-d avg
- 74.95
- 200-d avg
- 93.76
- 1y target
- 88.38
MAX chart
Events in this range
- Nov 3, 2014Dividend: 0.072
- Apr 7, 2015Dividend: 0.083
- Nov 3, 2015Dividend: 0.083
- Apr 5, 2016Dividend: 0.095
- Nov 1, 2016Dividend: 0.095
- Apr 4, 2017Dividend: 0.105
- Dec 1, 2022Dividend: 0.325
- Aug 5, 2025Earnings: 1.76; estimate 1.62; surprise 8.64%
- Nov 4, 2025Earnings: 1.7; estimate 1.62; surprise 4.94%
- May 7, 2026Earnings: 1.53; estimate 1.6; surprise -4.38%
- Aug 6, 2026Earnings: 1.87; estimate 1.85; surprise 1.08%
- Oct 30, 2026Dividend: 0.53
- Nov 5, 2026Earnings: —; estimate 1.51; surprise —%
Signals (53)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | May 1, 2026 | 6 months ago |
| SMA: Bearish | Dec 1, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 1, 2024 | 1 year ago |
| SMA: Bearish | Oct 1, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 1, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | Jun 1, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 1, 2024 | 2 years ago |
| SMA: Bearish | Mar 1, 2024 | 2 years ago |
| SMA: Bearish | Mar 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 1, 2023 | 2 years ago |
| SMA: Bullish | Nov 1, 2023 | 3 years ago |
| SMA: Bearish | Oct 1, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 1, 2023 | 3 years ago |
| SMA: Bearish | Sep 1, 2023 | 3 years ago |
| SMA: Bullish | Jul 1, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 1, 2023 | 3 years ago |
| SMA: Bullish | Jan 1, 2023 | 3 years ago |
| SMA: Bearish | Aug 1, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 1, 2022 | 4 years ago |
| SMA: Bearish | Jan 1, 2022 | 4 years ago |
| MACD: Buy Signal | May 1, 2021 | 5 years ago |
| RSI: Overbought | Apr 1, 2021 | 5 years ago |
| MACD: Sell Signal | Feb 1, 2021 | 5 years ago |
| RSI: Overbought | Jul 1, 2020 | 6 years ago |
| MACD: Buy Signal | May 1, 2020 | 6 years ago |
| RSI: Overbought | May 1, 2020 | 6 years ago |
| SMA: Bullish | Apr 1, 2020 | 6 years ago |
| MACD: Sell Signal | Apr 1, 2020 | 6 years ago |
| SMA: Bearish | Mar 1, 2020 | 6 years ago |
| MACD: Buy Signal | Mar 1, 2019 | 7 years ago |
| SMA: Bullish | Feb 1, 2019 | 7 years ago |
| RSI: Overbought | Feb 1, 2019 | 7 years ago |
| MACD: Sell Signal | Jan 1, 2019 | 7 years ago |
| SMA: Bearish | Dec 1, 2018 | 7 years ago |
| RSI: Overbought | May 1, 2017 | 9 years ago |
| MACD: Buy Signal | Dec 1, 2016 | 9 years ago |
| MACD: Sell Signal | Oct 1, 2016 | 10 years ago |
| MACD: Buy Signal | Aug 1, 2016 | 10 years ago |
| SMA: Bullish | Apr 1, 2016 | 10 years ago |
| SMA: Bearish | Jan 1, 2016 | 10 years ago |
| SMA: Bullish | Nov 1, 2015 | 11 years ago |
| SMA: Bearish | Aug 1, 2015 | 11 years ago |
| RSI: Overbought | Jul 1, 2015 | 11 years ago |
| RSI: Overbought | May 1, 2015 | 11 years ago |
| RSI: Overbought | Feb 1, 2015 | 11 years ago |
| RSI: Overbought | Nov 1, 2014 | 12 years ago |
| SMA: Bullish | Jun 1, 2014 | 12 years ago |
| SMA: Bearish | Mar 1, 2014 | 12 years ago |
| SMA: Bullish | Feb 1, 2014 | 12 years ago |
| SMA: Bearish | Jan 1, 2014 | 12 years ago |
| SMA: Bullish | Dec 1, 2013 | 12 years ago |
Key statistics
- Market cap
- 32.94B
- Enterprise value
- 40.14B
- Trailing P/E
- 13.11
- Forward P/E
- 12.44
- PEG ratio
- 14.67
- Price / sales
- 3.46
- Price / book
- 10.49
- EPS (TTM)
- 6.08
- Beta
- 0.74
- Dividend yield
- 2.69%
- Payout ratio
- 33.88%
- Profit margin
- 27.68%
- Revenue (TTM)
- 9.53B
- Revenue growth
- -0.20%
- Free cash flow
- 2.02B
- Total cash
- 1.68B
- Total debt
- 9.26B
- Return on equity
- 64.91%
- Shares outstanding
- 413.22M
- Short % of float
- 4.80%
- 50-day average
- 74.95
- 200-day average
- 93.76
Analyst view
Consensus: hold
Hold
Price target (mean) 88.38 +10.9% upside
Now 79.72
- Target (low)
- 74.00
- Target (mean)
- 88.38
- Target (high)
- 115.00
Ratings (0m) 16 5 buy · 11 hold · 0 sell
- Strong buy3
- Buy2
- Hold11
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 1.51.
Financials — quick view
ZTS Revenue — quarterly 2.47B
ZTS Net income — quarterly 691.00M
ZTS EPS — quarterly 1.65
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 1.51 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 1.85 | 1.87 | +0.02 | +1.08% |
| May 7, 2026 | Mar 31, 2026 | 1.60 | 1.53 | -0.07 | -4.38% |
| Feb 12, 2026 | Dec 31, 2025 | 1.40 | 1.48 | +0.08 | +5.71% |
| Nov 4, 2025 | Sep 30, 2025 | 1.62 | 1.70 | +0.08 | +4.94% |
| Aug 5, 2025 | Jun 30, 2025 | 1.62 | 1.76 | +0.14 | +8.64% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 27, 2026 | UBS | main | Neutral | Neutral |
| Oct 20, 2026 | Jefferies | down | Buy | Hold |
| Oct 16, 2026 | Goldman Sachs | init | — | Neutral |
| Aug 25, 2026 | TD Cowen | main | Buy | Buy |
| Aug 20, 2026 | Stifel | main | Hold | Hold |
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- zoetis.com
News
- Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note
- Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $82
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- UBS Maintains Neutral on Zoetis, Raises Price Target to $85
- 3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
- Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?
- Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
- ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
- Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
- This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Your note
Sign in to keep a note on ZTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BISARO PAUL M. | Director | Purchase | May 12, 2026 | 27,862 |
| D AMELIO FRANK A | Director | Stock Gift | Aug 6, 2026 | 21,458 |
| JOSEPH WETTENY | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 20,766 |
| LAGANO ROXANNE | Officer | Conversion of Exercise of derivative security | Feb 18, 2026 | 16,465 |
| MCCALLISTER MICHAEL B | Director | Stock Gift | Jun 9, 2026 | 31,893 |
| NORDEN GREGORY | Director | Stock Gift | Mar 8, 2026 | 18,167 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.54% | 39,430,181 | 3.14B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.30% | 26,027,984 | 2.07B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.77% | 23,860,445 | 1.90B | Jun 29, 2026 |
| State Street Corporation | 4.76% | 19,667,723 | 1.57B | Jun 29, 2026 |
| State Farm Mutual Automobile Insurance Co | 3.85% | 15,892,903 | 1.27B | Jun 29, 2026 |
| Geode Capital Management, LLC | 3.22% | 13,289,622 | 1.06B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.90% | 11,982,269 | 955.11M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.63% | 10,862,724 | 865.87M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 1.98% | 8,175,936 | 651.70M | Jun 29, 2026 |
| VANGUARD FENWAY FUNDS-Vanguard Equity Income Fund | 1.48% | 6,106,220 | 486.73M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 5,506,516 | 438.92M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.32% | 5,441,955 | 433.78M | Aug 30, 2026 |